share_log

Optimism Around ApicHope Pharmaceutical (SZSE:300723) Delivering New Earnings Growth May Be Shrinking as Stock Declines 15% This Past Week

株価が15%下落した先週、apichope pharmaceutical(SZSE:300723)の新しい収益成長の期待感が薄れているかもしれません

Simply Wall St ·  08/02 20:34

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. For example, the ApicHope Pharmaceutical Co., Ltd (SZSE:300723) share price is down 35% in the last year. That's well below the market decline of 18%. Even if you look out three years, the returns are still disappointing, with the share price down33% in that time. Shareholders have had an even rougher run lately, with the share price down 30% in the last 90 days.

Since ApicHope Pharmaceutical has shed CN¥1.2b from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Unhappily, ApicHope Pharmaceutical had to report a 47% decline in EPS over the last year. The share price fall of 35% isn't as bad as the reduction in earnings per share. So the market may not be too worried about the EPS figure, at the moment -- or it may have expected earnings to drop faster.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

big
SZSE:300723 Earnings Per Share Growth August 3rd 2024

It might be well worthwhile taking a look at our free report on ApicHope Pharmaceutical's earnings, revenue and cash flow.

A Different Perspective

We regret to report that ApicHope Pharmaceutical shareholders are down 34% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for ApicHope Pharmaceutical that you should be aware of.

We will like ApicHope Pharmaceutical better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする